Q1 Earnings Forecast for COYA Issued By HC Wainwright

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at HC Wainwright issued their Q1 2027 EPS estimates for Coya Therapeutics in a research note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.66) EPS.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). The company had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%.

Several other equities analysts have also issued reports on COYA. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research report on Monday, March 16th. D. Boral Capital reissued a “buy” rating and set a $15.00 price objective on shares of Coya Therapeutics in a research report on Monday, March 16th. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $16.00.

Coya Therapeutics Trading Up 0.2%

Coya Therapeutics stock opened at $4.22 on Tuesday. Coya Therapeutics has a 12 month low of $3.94 and a 12 month high of $7.75. The company has a market capitalization of $99.00 million, a price-to-earnings ratio of -3.32 and a beta of 0.23. The business’s fifty day simple moving average is $4.68 and its two-hundred day simple moving average is $5.50.

Institutional Investors Weigh In On Coya Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. purchased a new position in shares of Coya Therapeutics in the 4th quarter worth $4,640,000. AWM Investment Company Inc. purchased a new stake in Coya Therapeutics during the fourth quarter valued at $4,205,000. CM Management LLC lifted its holdings in Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after acquiring an additional 50,000 shares during the period. Private Management Group Inc. bought a new position in Coya Therapeutics in the fourth quarter valued at about $1,626,000. Finally, Marshall Wace LLP boosted its position in Coya Therapeutics by 438.8% in the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock worth $1,307,000 after purchasing an additional 183,533 shares during the last quarter. Institutional investors own 39.75% of the company’s stock.

Trending Headlines about Coya Therapeutics

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and an $18 price target on COYA, representing a large upside from current levels; the firm cites pipeline potential and upcoming program catalysts as the rationale. Benzinga
• Positive Sentiment: A TipRanks summary of HC Wainwright’s coverage emphasizes Coya’s advancing Treg‑focused pipeline and near‑term catalysts (ALS and FTD) as supporting the Buy rating and long‑term upside thesis. Coya Therapeutics: Advancing Treg-Focused Pipeline…
• Neutral Sentiment: Reported short‑interest data for March show effectively zero shares on file and a 0.0 days‑to‑cover figure — an odd/ambiguous data point that neither clearly pressures nor supports the stock given the lack of meaningful short activity.
• Negative Sentiment: HC Wainwright’s updated 2027 forecasts show deeper quarterly and full‑year losses than the market consensus (FY2027 EPS forecast of -$1.66 vs. consensus -$1.15), which could concern investors focused on near‑term dilution and cash needs despite the Buy rating.
• Negative Sentiment: Recent company results (reported March 16) showed an EPS miss for the quarter (reported -$0.34 vs. -$0.08 expected) despite revenue beating estimates; continued quarterly losses and negative margins remain a risk to sentiment until clear clinical or commercial readouts reduce execution uncertainty.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.